Literature DB >> 18830927

Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes.

Simon A Hinke1.   

Abstract

Diamyd Medical AB is developing Diamyd (GAD-65), an alum formulation of a full-length recombinant human glutamic acid decarboxylase 65 for subcutaneous injection, for the potential prevention and treatment of type 1 diabetes (T1DM) or latent autoimmune diabetes (LADA) in adults. Phase II clinical trials indicated that Diamyd was safe and well tolerated in patients with T1DM or LADA. Diamyd is currently in phase II/III and III clinical trials for T1DM.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18830927

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  6 in total

1.  A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.

Authors:  Gisela M Vaitaitis; Martin G Yussman; David H Wagner
Journal:  J Neuroimmunol       Date:  2019-03-21       Impact factor: 3.478

2.  Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

3.  Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.

Authors:  Damien Bresson; Matthew Fradkin; Yulia Manenkova; Diane Rottembourg; Matthias von Herrath
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

4.  A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.

Authors:  Gisela M Vaitaitis; Michael H Olmstead; Dan M Waid; Jessica R Carter; David H Wagner
Journal:  Diabetologia       Date:  2014-08-08       Impact factor: 10.122

Review 5.  Baculoviruses in Gene Therapy and Personalized Medicine.

Authors:  Sabrina Schaly; Merry Ghebretatios; Satya Prakash
Journal:  Biologics       Date:  2021-04-28

6.  Association of CLTA-4 Gene Polymorphisms with Diabetes Mellitus: A Study Based on the Han Population of Northern China.

Authors:  Dongyue Ren; Lin He; Xiaoling Pang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-09-03       Impact factor: 3.249
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.